Form 4: Neurogene Inc. CFO Christine Mikail Reports Stock Option Grant and Common Stock Transaction

Christine Mikail, President and CFO of Neurogene Inc., reports the acquisition of stock options and a transaction involving common stock on March 13, 2024.

Summary

• On March 13, 2024, Christine Mikail, the President and CFO of Neurogene Inc., reported a transaction.
• She acquired 53,900 employee stock options with an exercise price of $36.06, expiring on March 13, 2034.
• These options vest over time, starting with 1/4 on March 13, 2025, and then 1/48 monthly thereafter, contingent on continued service.
• Mikail also acquired 31,903 shares of common stock at $0 and disposed of 52,844 shares of common stock.
• Following these transactions, she directly owns 52,844 shares of common stock and 53,900 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions. The stock option grant is a positive sign, but the disposal of shares is a slightly negative sign.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry where stock options are frequently used to incentivize management.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning management's interests with theirs.
• Employees may view the stock option grant as a positive sign of the company's commitment to its leadership.

Key Dates